全文获取类型
收费全文 | 4319篇 |
免费 | 446篇 |
国内免费 | 13篇 |
专业分类
耳鼻咽喉 | 45篇 |
儿科学 | 220篇 |
妇产科学 | 158篇 |
基础医学 | 537篇 |
口腔科学 | 60篇 |
临床医学 | 495篇 |
内科学 | 1279篇 |
皮肤病学 | 37篇 |
神经病学 | 211篇 |
特种医学 | 197篇 |
外国民族医学 | 1篇 |
外科学 | 842篇 |
综合类 | 55篇 |
一般理论 | 2篇 |
预防医学 | 228篇 |
眼科学 | 55篇 |
药学 | 128篇 |
1篇 | |
中国医学 | 6篇 |
肿瘤学 | 221篇 |
出版年
2019年 | 48篇 |
2018年 | 52篇 |
2017年 | 65篇 |
2016年 | 51篇 |
2015年 | 45篇 |
2014年 | 90篇 |
2013年 | 126篇 |
2012年 | 123篇 |
2011年 | 139篇 |
2010年 | 97篇 |
2009年 | 81篇 |
2008年 | 131篇 |
2007年 | 139篇 |
2006年 | 149篇 |
2005年 | 161篇 |
2004年 | 127篇 |
2003年 | 116篇 |
2002年 | 102篇 |
2001年 | 127篇 |
2000年 | 113篇 |
1999年 | 101篇 |
1998年 | 65篇 |
1997年 | 58篇 |
1996年 | 60篇 |
1995年 | 61篇 |
1994年 | 70篇 |
1993年 | 45篇 |
1992年 | 83篇 |
1991年 | 91篇 |
1990年 | 91篇 |
1989年 | 108篇 |
1988年 | 110篇 |
1987年 | 83篇 |
1986年 | 110篇 |
1985年 | 106篇 |
1984年 | 79篇 |
1983年 | 84篇 |
1982年 | 48篇 |
1981年 | 49篇 |
1980年 | 47篇 |
1979年 | 67篇 |
1978年 | 69篇 |
1977年 | 55篇 |
1976年 | 57篇 |
1975年 | 70篇 |
1974年 | 78篇 |
1973年 | 69篇 |
1972年 | 62篇 |
1970年 | 47篇 |
1967年 | 48篇 |
排序方式: 共有4778条查询结果,搜索用时 0 毫秒
1.
There is a sharp difference in how one views TCR structure–function–behaviour dependent on whether its recognition of major histocompatibility complex‐encoded restriction elements (R) is germline selected or somatically generated. The generally accepted or Standard model is built on the assumption that recognition of R is by the V regions of the αβ TCR, which is not driven by allele specificity, whereas the competing model posits that recognition of R is allele‐specific. The establishing of allele‐specific recognition of R by the TCR would rule out the Standard model and clear the road to a consideration of a competing construct, the Tritope model. Here, the case for allele‐specific recognition (germline selected) is detailed making it obvious that the Standard model is untenable. 相似文献
2.
3.
Jennifer Wang Jonathan G. Stine Scott L. Cornella Curtis K. Argo Steven M. Cohn 《临床与转化肝病杂志(英文版)》2015,3(4):254-259
Background and Aims: Gastric antral vascular ectasia (GAVE) is commonly found in patients with cirrhosis, but it is also associated with other diseases in the absence of cirrhosis. Whether GAVE confers a different severity of gastrointestinal (GI) bleeding between patients with and without cirrhosis remains unknown. We aim to examine whether there is a difference in clinically significant GI bleeding due to GAVE in patients with or without cirrhosis. Methods: This is a retrospective case-control study of patients who were diagnosed with GAVE between January 2000 and June 2014. Patients were categorized into cirrhosis and noncirrhosis groups, and those with an additional GI bleeding source were excluded. Univariate comparisons and multivariable models were constructed using logistic regression. Results: In total, 110 patients diagnosed with GAVE on esophagogastroduodenoscopy (EGD) were included in our analysis; 84 patients had cirrhosis (76.4%) and 26 (23.6%) did not. Active GI bleeding was more prevalent in patients without cirrhosis (63.4% vs. 32.1%, p=0.003) despite similar indications for EGD, and endoscopic treatment with argon plasma coagulation (APC) was required more often in this group, approaching statistical significance (27% vs. 10.7%, p=0.056). There was no difference in bleeding severity, as evidenced by similar re-bleeding rates, surgery, or death attributed to uncontrolled bleeding. The strongest independent risk factor for GI bleeding was the absence of cirrhosis (odds ratio (OR): 5.151 (95% confidence interval (CI): 1.08-24.48, p=0.039). Conclusions: Patients with GAVE in the absence of cirrhosis are at higher risk for active GI bleeding and require more frequent endoscopic treatment than similar patients with cirrhosis. It may be worthwhile to treat GAVE in this population even in the absence of active bleeding. 相似文献
4.
Jay N Cohn 《Journal of the American College of Cardiology》2006,48(3):430-433
Mortality and morbid events are insensitive guides to the efficacy and safety of interventions in chronic cardiovascular disease (CVD). To enhance the ability to find new and effective long-term treatments, especially for the early stages of CVD, a revised strategy for clinical trials should emphasize efficacy on disease progression while monitoring symptoms and quality of life as guides to clinical benefit. Mortality, which is uncommon except in acute or advanced disease, provides at best a crude guide to net efficacy and safety. It must be monitored to support demonstrated efficacy on disease progression without adverse safety effects. This revised approach, made possible by our enhanced ability to monitor the progression of disease, should make it possible to study earlier disease and to improve cardiovascular health while reducing health care costs. 相似文献
5.
6.
7.
8.
Ketai LH; Williamson MR; Telepak RJ; Levy H; Koster FT; Nolte KB; Allen SE 《Radiology》1994,191(3):665
9.
10.